

The Protein Sequencing CompanyTM

Corporate Presentation

January 2023





Disclaimer

Cautionary Note Regarding Forward-Looking Statements

This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results of Quantum-Si Incorporated (the "Company") may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forwardlooking statements as predictions of future events. Words such as "expect," "estimate," "project," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance, development of products and services, potential regulatory approvals, the size and potential growth of current or future markets for the Company's future products and services, or the Company's plans expectations or future operations, financial position, revenues, costs or expenses. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's shares of Class A common stock on The Nasdag Stock Market; the ability to recognize the benefits of the Company's business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the Company's ability to raise financing in the future; the success, cost and timing of the Company's product development activities; the potential attributes and benefits of the Company's products and services; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company's future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services following commercial launch; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

QUANTUM-SI 2

Quantum-Si: The Protein Sequencing Company™



Experienced Team

From life sciences leaders including Illumina, Millipore Sigma, and Ion Torrent

192

Employees

\$372M

Cash as of end of 3Q22



Time Domain Sequencing[™]

Novel method sequences peptides at the amino acid level in a massively parallel fashion on a semiconductor chip

>1,000

Patents issued & applications pending

Peer-Reviewed Technology

Published in Science in October 2022




Launched PlatinumTM, the world's first next-generation single-molecule protein sequencing platform, in December 2022

First orders received and **shipping** has started

Proteomics market opportunity valued at \$50B+1



Unlocking the Value of the Proteome



Proteins are the main structural and functional components of cells and they are extremely diverse

Protein modifications are real-time indicators of health and disease, making them ideal markers for disease, drug response and health


85% of the human proteome is currently undrugged¹, potential for game changing drug development


Next-generation, single-molecule protein sequencing provides an unbiased view of amino acid mutations and post-translational modifications (PTMs) that can be missed by affinity-based methods

1. A Quest to Drug the Undruggable, June 2018, Chemical & Engineering News

QUANTUM-S

Large and Growing Market Opportunity





The Quantum-Si Solution



Sample Prep

CARBON (Launching in 2023)

Universal cartridge based sample preparation and automation



Sequencing & Cloud Analysis

PLATINUM

Massively Parallel, Single Molecule Detection



Reagents & Chips

CONSUMABLES

Library Prep & Protein Sequencing

Next-generation


Accessible

Proven




OLIANTIIM_C

Quantum-Si's Technology: Time Domain Sequencing



Massively parallel analysis on a semiconductor chip








QUANTUM-SI

Post-Translational Modifications: See What Others Can't


- Single-molecule binding kinetics
 enables the detection of PTMs
 without the need to develop new
 affinity reagents (no a priori
 knowledge is needed)
- ADMA and SDMA have distinct kinetic signatures despite having identical mass
- Quantum-Si technology can unlock the ability to study complex disease pathways and discover novel biomarkers





ANTUM-SI

Accessible to Any Lab, Anywhere




Benchtop instrument

Low capital cost


Leverages standard laboratory workflow

Simplified and automated data analysis




Data Analysis – Automated and Easy to Interpret

Data from Mass Spectrometry Core Lab



Data from Quantum-Si analysis software



10

OUANTUM-SI

Proven Team and Technology








Proven Team

From leading life sciences companies



>1,000

Patents issued and patent applications

Science

Real-time dynamic single-molecule protein sequencing on an integrated semiconductor device


Brian D. ReedMichael J. MeyerValentin Abramzon, and Omer Ad PhDOmer AdPat AdoockFaisal R. AhmadGün AlppayJames A. Ballames BeachDominique BelhachemiAntony BeliofioreMichael BellosJuan Felipe BetránnAndrew BestsMchammad Wadud Bhulyak/sitsin Bickokck/Robert BeerDavid BoisvertNorman. D. BrautJAvanon BuchaumSteve Caprischanghoon CholThomas D. ChristianRobert ClancyJoseph ClarkThomas CornollyKathren Fink CroceRichaed CullenMel DaveyJack DavidsonMchamed M. ElshenawyMichael FerrignoDaniel FrierSaketh GudpatiStephanie HamiliZhaoyu HeSharath HosalHaidong HuangLe HuangAli KabinGennady KrigerBittany LathropAn LiPoter LimStephen LiuFeixiang LuoCaixia LyXiaoxiao MaEvan McCormackMichael MilhamRoger NaniManjula PandeyJohn Parallo Patel PetstonAdeline Pichael-Koschickyle ReariskTodd ReariskMarco Ribezzi-ChvellariGerard SchmidJonathan SchultzXinghua ShiBadri SinghNikita SrivastavaShannon F. Stewman, and TR ThurstonT. R. ThurstonPhilip TriolJennifer TulmanXin WangYen-Chih WangEric A. G. WebsterZhizhuo ZhangJorge ZurigaSmita S. PatelAndew D. GriffithsAntione M. van OigenMichael McKennaMatthew D. DyecJonathan M. Rothberg

Science, 378 (6616), • DOI: 10.1126/science.abo7651

Peer-reviewed in *Science*October 2022

Quantum-Si is Uniquely Differentiated from the Competition


	Quantum-Si	Encodia	Erisyon	Nautilus	SomaLogic	Olink
Commercially Available	⊘	x	x	Х	②	⊘
Technology	Direct kinetic sequencing	Binding + Degradation with NGS readout	Labeling + Degradation with scanning	Aptamers/Antibodies	Aptamers	Antibodies
Instrument Cost	\$	\$\$\$*	\$\$	\$\$\$	\$\$-\$\$\$**	\$-\$\$\$**
Run Cost	\$	\$\$-\$\$\$*	\$\$	\$\$-\$\$\$	\$\$-\$\$\$**	\$-\$\$\$**
AA Sequencing	⊘	Limited	Limited	X	X	X
PTM Detection	⊘	?	Requires special reagent	?	Requires PTM specific reagent development	
Automated Data Analysis	⊘	?	?	?	?	?




Note: *NGS instrument required; **NGS instrument optional

Digital Technologies Can Transform Markets

The analog to digital transition creates new market opportunities – we have seen this before



Commercial Priorities in 2023



Building the Protein Sequencing Ecosystem

Establishing industry partnerships to enhance the end-to-end customer experience



Proteomics Sample Prep

- Co-Development of Immunoprecipitation kits
- Access to +15K different antibodies
- Sample prep solution for customers engaged in targeted proteomics



• Vizit provides a custom visualization tool to determine relationships between proteins identified and other features such as PTMs, diseases, or drug mechanisms-of-action

Quantum-Si is Well-Positioned for a Successful 2023



Commercialize Platinum, Carbon and 2M Chip

Achieved 4Q22 Platinum Launch; Shipping underway; Focus on generating independent data & publications throughout 2023; Launching Carbon in 2023



Lead with Innovation

Deliver new data analysis tools and expanded proteome coverage throughout 2023



Preserve Financial Strength

Continued fiscal discipline; Committed to extend cash runway beyond current guidance



The Protein Sequencing CompanyTM

Q&A

